Welcome to the newly redesigned ASHClinicalNews.org! As you navigate the site, please send any feedback/issues to [email protected].
A Cure for Congress?
An Interview With Jason Westin, MD
As a hematologist and researcher, Jason Westin, MD, has dedicated his career to expanding and advancing treatment options for patients with lymphomas. Now, he’s turning that focus to the American health-care...
Online Exclusives
Cancer Deaths Occur More in Rural America According to CDC Report
According to a new report from the Centers for Disease Control and Prevention (CDC), rates of cancer-related deaths are higher for people living in...
FDA Approves First New Sickle Cell Treatment in Nearly 20 Years
The U.S. Food and Drug Administration (FDA) has approved L-glutamine oral powder to reduce severe complications associated with sickle cell disease (SCD) in patients...
News
From the Blood Journals
Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk...
Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...
Population-Based Study Finds Persistent Gaps in Understanding and Identification of VTE...
An estimated 500,000 venous thromboembolism (VTE) events occur annually in the United States, about half of which are related to current or recent hospitalizations,...
Latest Videos
Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML
Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell...
Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL
Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas
Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...
On Location
Evaluating a Risk-Adapted Treatment Approach in Younger Patients With AML
A risk-adapted approach incorporating minimal residual disease (MRD) and cytogenetic data could help identify patients...
Danazol Plus ATRA Safe and Effective in Corticosteroid- Resistant/Relapsed ITP
According to results from a multicenter, prospective study presented at the 22nd Congress of the...
CC-122 Plus Obinutuzumab Effective in Relapsed/Refractory B-Cell NHL
Combining the anti-CD20 monoclonal antibody obinutuzumab with the first-in-class pleiotropic pathway modifier CC-122 led to...
Updated Results From ZUMA-1 Show “Promising” Response Rates With CAR T-Cell Therapy in Relapsed/Refractory NHL
Treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a high...
Evaluating the Hedgehog Inhibitor Glasdegib in Patients With Heavily Pretreated Myelofibrosis
In a phase Ib/II trial of patients with myelofibrosis whose disease did not respond to...
Forty Percent of Patients With Previously Treated IDH2-Mutated AML Respond to Enasidenib
For the approximately 12 percent of patients with acute myeloid leukemia (AML) with the IDH2...
Latest Headlines
ASH Directions
ASH Co-Hosts Congressional Briefing on Sickle Cell Disease, Blood Journal’s Impact On the Rise,...
ASH Co-Hosts Congressional Briefing on Sickle Cell DiseaseThe American Society of Hematology (ASH) co-hosted a congressional briefing on sickle cell disease (SCD) and gene...
AML Matters Summit, ASH President Participates in LLS Panel Discussion, and more
AML Matters Summit Continues Across U.S.
AML Matters is a free educational program designed to provide guidance to health-care professionals on the optimal diagnosis and...
Remembering H. Jean Khoury, NCI Funds Standardization of Cancer Genomic Data, and more
Remembering H. Jean Khoury (1967-2017)
H. Jean Khoury, MD, an expert in hematologic malignancies at the Winship Cancer Institute of Emory University, died at age...
Remembering Neil Abramson, MD, AACC Announces Clinical Chemistry Trainee Council Educational Initiative, and more
Remembering Neil Abramson, MD (1937-2017)
Neil Abramson, MD, a hematologist/oncologist who served as a Blood Special Section Editor from 2008-2012, passed away at the age...
ASH 2017 Bridge Grant Awards, Hematologists Receive Stand Up To Cancer 2017 Innovative Research...
ASH Announces 2017 Bridge Awards
The American Society of Hematology (ASH) announced the names of five investigators who have received the latest round of ASH...
It Runs in the Blood
For these doctors, hematology is “the family business”
The term “family business” may conjure images of stores, restaurants, and other commercial enterprises, but it turns...
Show Me the Money? Show Us the Data!
How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers?
The merits and cautions of data sharing have long been a...
Uncommon Presentations, Uncommon Cancers
In this column, Beth Faiman, CNP, PhD, reviews the 5th edition of the Textbook of Uncommon Cancer.
Have you read any hematology-related books recently? Let...
